Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) has provided an update.
Venus Medtech (Hangzhou) Inc. has agreed to dispose of its entire remaining stake in an unnamed investee company, selling approximately 1.05% of the investee’s fully diluted share capital for US$15 million to a wholly owned subsidiary of Broncus. The transaction, classified as a discloseable transaction under Hong Kong listing rules, will result in Venus Medtech’s subsidiary exiting its investment in the company entirely, signaling a reallocation of capital that could support the group’s core operations while modestly reshaping its investment portfolio without triggering higher-level shareholder approval requirements.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a PRC-incorporated medical technology company listed in Hong Kong, focused on developing and commercializing innovative cardiovascular devices and related medical technologies, with a market presence geared toward advanced interventional treatments.
Average Trading Volume: 1,803,710
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.09B
See more insights into 2500 stock on TipRanks’ Stock Analysis page.